INSIGHTS ON UPSTREAM MANUFACTURING
-
![GettyImages-1407359737-dna-gene]( "Solving The DNA Knock-In Problem")
Solving The DNA Knock-In ProblemAn in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.
-
![cell-therapy-GettyImages-1494029118]( "Expanding The Capabilities Of Targeted Integration")
Expanding The Capabilities Of Targeted IntegrationSee the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.
-
![Lonza DNA IND webinar]( "From DNA To IND In As Little As 6 Months")
From DNA To IND In As Little As 6 MonthsDiscover how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment.
-
![GettyImages-1158724314-electorphoresis-hand-filling-cell]( "ESACT 2026: Reducing Variability With Animal‑Origin‑Free Peptones")
ESACT 2026: Reducing Variability With Animal‑Origin‑Free PeptonesExplore how data‑driven collaboration and animal‑origin‑free media strategies can reduce variability, improve cell culture performance, and support consistent, cost‑effective bioprocessing at scale.
-
Providing Solutions In Titer, Host Cell Protein, And Scalability4/23/2026
By leveraging expertise across a global network and executing a streamlined, rapid technology transfer, see how we were able to enable a highly data-driven approach to clone selection and process optimization.
-
Scale Up Or Scale Out? Choosing An Adherent Cell Culture Platform4/21/2026
Facility space costs up to $1,000/sq ft and planning timelines stretch 18 months, making your adherent cell culture platform choice one of the highest-stakes decisions in vaccine manufacturing scale-up.
-
Aligning Upstream And Downstream Development (Part 1)4/20/2026
In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.
-
Where Sourcing Meets Science: Smarter Collaboration, Better Outcomes4/20/2026
See how collaboration-driven raw material control reduces variability, improves cell culture performance, and delivers measurable cost and productivity gains in biotherapeutic manufacturing.
UPSTREAM MANUFACTURING SOLUTIONS
-
![GettyImages-1626470215-cluster-cells-stem-cells-blue]( "Cell Therapy Selection Guide: Connected From Activation To Expansion")
Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.
-
![Thermo - DynActivator]( "Integrated T Cell Activation: Soluble DynActivator CD3/CD28 Prototype")
Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.
-
![RoosterBio - RoosterVial]( "Xeno-Free (XF) Human Dermal Fibroblasts")
Learn how xeno-free human dermal fibroblasts achieve over 1 billion cells in 10 days through optimized 2D and 3D expansion protocols designed for clinical-scale therapeutic manufacturing applications.
-
![RoosterBio]( "RoosterReplenish™ hMSC Bioreactor Feed")
A concentrated bioreactor feed, RoosterReplenish-MSC-XF & prcRoosterReplenish-MSC-CC enable a fed-batch process for scalable, translation-ready cGMP hMSC manufacturing.
-
![GettyImages-172670893-cell-bank-cyropreservation-liquid-nitrogen]( "BioRepository Services")
Reliable sample protection comes from secure facilities. Learn how multiple storage formats, split‑site options, and full audit trails help ensure biological materials remain ready for future use.
